Choose your country to see the products for your location

SALSA MLPA Probemix P064 Microdeletion Syndromes-1B

SALSA® MLPA® Probemix P064 Microdeletion Syndromes-1B detects a subset of recurrent microdeletions and microduplications.

Specifications

Contents: 52 MLPA probes targeting various chromosomal regions involved in microdeletion and microduplication syndromes.

Tissue: genomic DNA isolated from human peripheral whole blood, buccal swabs or specified prenatal samples (see Intended Purpose).

Application: developmental delay, intellectual disability and/or congenital anomalies. See full list of syndromes in the Intended Purpose.

CE-marked and registered for in vitro diagnostic (IVD) use in selected territories.

Quick links

List Prices Documentation

Key related products

SALSA MLPA Probemix P036 Subtelomeres Mix 1

This probemix contain probes for subtelomeric regions.

SALSA MLPA Probemix P070 Subtelomeres Mix 2B

This probemix contain probes for subtelomeric regions.

SALSA MLPA Probemix P106 X-linked ID

Contains probes for various genes involved in X-linked intellectual disability.

View all

Intended purpose

The SALSA MLPA Probemix P064 Microdeletion Syndromes-1B is an in vitro diagnostic (IVD) or research use only (RUO) semi-quantitative assay for the detection of a distinct subset of recurrent microdeletions and microduplications (mentioned in the table below) in genomic DNA isolated from human peripheral whole blood, buccal swabs, (un)cultured amniotic fluid obtained in week 16 of the pregnancy or later and free from blood contamination, (un)cultured chorionic villi free from maternal contamination, or foetal blood specimens. P064 Microdeletion Syndromes-1B is intended to confirm a potential cause for and clinical diagnosis of developmental delay, intellectual disability and/or congenital anomalies.

Syndromes that can be detected by the P064 probemix
Syndrome Genetic locus OMIM Number of probes
1p36 deletion syndrome 1p36 607872 4
Wolf-Hirschhorn syndrome 4p16.3 194190 4
Cri-du-Chat syndrome 5p15 123450 5
Sotos syndrome 5q35.3 117550 3
Saethre-Chotzen syndrome 7p21.1 101400 2
Williams-Beuren syndrome 7q11.23 194050 3
Williams-Beuren duplication syndrome 7q11.23 609757
Trichorhinophalangeal syndrome type 2 8q24.11-q24.13 150230 3
WAGR syndrome 11p13 194072 3
Prader-Willi syndrome 15q11.2 176270 4
Angelman syndrome 15q11.2 105830
Rubinstein-Taybi syndrome 16p13.3 180849 2
Miller-Dieker syndrome 17p13.3 247200 4
Lissencephaly-1 17p13.3 607432
Smith-Magenis syndrome 17p11.2 182290 4
Potocki-Lupski syndrome 17p11.2 610883
Alagille syndrome 20p12.2 118450 2
DiGeorge syndrome 22q11.21 188400 7
22q11.2 microduplication syndrome 22q11.2 608363
Phelan-McDermid syndrome 22q13 606232 2

For the full intended purpose, see the product description.

Clinical background

Microdeletion and microduplication syndromes are defined as a group of clinically recognisable disorders characterised by a small (< 5 Mb) deletion or duplication of a chromosomal segment spanning one or multiple disease genes. The phenotype is the result of haploinsufficiency or overexpression of specific genes in the critical interval. Clinically well described syndromes, for which the involvement of multiple disease genes has been established or is strongly suspected, include DiGeorge syndrome (22q11 microdeletion), Williams-Beuren syndrome (7q11 microdeletion), Smith-Magenis Syndrome (17p microdeletion) and many more. Most patients with microdeletion/microduplication syndromes present with intellectual disability (ID), developmental delay (DD), congenital abnormalities and/or dysmorphic features.

Intellectual disability and developmental delay affects 1–3% of the population and results from extraordinary heterogeneous environmental, chromosomal and monogenic causes. Detailed analysis of the Online Mendelian Inheritance in Man (OMIM) database and literature searches revealed more than a thousand entries for ID and DD, and more than 290 genes involved in clinical phenotypes or syndromes, metabolic or neurological disorders characterised by ID/DD.

The genetic changes of microdeletions/duplications are often not detectable by the current band resolution using routine or high resolution karyotyping (2-5 Mb) but require the application of molecular cytogenetic techniques such as Fluorescence In Situ Hybridisation (FISH), MLPA or array Comparative Genomic Hybridisation (aCGH).

Regulatory status

SALSA MLPA Probemix P064 Microdeletion Syndromes-1B is CE-marked for in vitro diagnostic (IVD) use. This assay has also been registered for IVD use in Israel.

This assay is for research use only (RUO) in all other territories.

Product documentation

Version C2

Other versions

Contact us for earlier versions.

List prices

Product

Item no.
Description
Technology
Price
P064-025R
SALSA MLPA Probemix P064 Microdeletion Syndromes-1B – 25 rxn
MLPA
€ 281.00
P064-050R
SALSA MLPA Probemix P064 Microdeletion Syndromes-1B – 50 rxn
MLPA
€ 550.00
P064-100R
SALSA MLPA Probemix P064 Microdeletion Syndromes-1B – 100 rxn
MLPA
€ 1075.00

Required reagents

A general SALSA MLPA Reagent Kit is required for MLPA experiments (to be ordered separately).

Item no.
Description
Technology
Price
EK1-FAM
SALSA MLPA Reagent Kit – 100 rxn – FAM (6 vials)
MLPA MS-MLPA
€ 341.00
EK1-Cy5
SALSA MLPA Reagent Kit – 100 rxn – Cy5 (6 vials)
MLPA MS-MLPA
€ 341.00
EK5-FAM
SALSA MLPA Reagent Kit – 500 rxn – FAM (5×6 vials)
MLPA MS-MLPA
€ 1571.00
EK5-Cy5
SALSA MLPA Reagent Kit – 500 rxn – Cy5 (5×6 vials)
MLPA MS-MLPA
€ 1571.00
EK20-FAM
SALSA MLPA Reagent Kit – 2000 rxn – FAM (5×6 vials)
MLPA MS-MLPA
€ 6037.00

Price details & ordering

The prices above are list prices for direct orders from MRC Holland. Contact us for a quote that takes discounts and additional costs (such as shipping costs) into account. Different prices apply for orders through one of our sales partners; contact your local supplier for a quote.

More information about ordering & prices

Positive samples

Inclusion of a positive sample is usually not required, but can be useful for the analysis of your experiments. MRC Holland has very limited access to positive samples and cannot supply such samples. We recommend using positive samples from your own collection. Alternatively, you can use positive samples from an online biorepository, such as the Coriell Institute.

The commercially available positive samples below have been tested with the current (C2) version of this product and have been shown to produce useful results.

  • Coriell NA22991: Heterozygous deletion affecting the probes for TNFRSF4, GABRD, PEX10 and ACTRT2 on chromosome 1p. 1p36 deletion syndrome.
  • Coriell NA22601: Heterozygous deletion affecting the probes for TACC3 and WHSC1 on chromosome 4p. Wolf-Hirschhorn syndrome.
  • Coriell NA14131: Heterozygous deletion affecting the probes for TERT, CLPTM1L, IRX4 and CTNND2 on chromosome 5p. Cri-du-Chat syndrome.
  • Coriell NA10160: Heterozygous deletion affecting the probes for ELN on chromosome 7q. Williams-Beuren syndrome.
  • Coriell NA09888: Heterozygous deletion affecting the probes for TRPS1, EIF3H and EXT1 on chromosome 8q. Trichorhinophalangeal syndrome type 2.
  • Coriell NA21887: Heterozygous deletion affecting the probes for SNRPN and UBE3A on chromosome 15q. Angelman syndrome.
  • Coriell NA06047: Heterozygous deletion affecting the probes for METTL16 and PAFAH1B1 on chromosome 17p. Miller-Dieker syndrome.
  • Coriell NA13476: Heterozygous deletion affecting the probes for RAI1 and TOM1L2 on chromosome 17p. Smith-Magenis syndrome.
  • Coriell NA17942: Heterozygous deletion affecting the probes for CLTCL1, CDC45, GNB1L, DGCR8, ZNF74, MED15 and SNAP29 on chromosome 22q. DiGeorge syndrome.

Resources

General MLPA resources

MLPA education

This site uses cookies to help improve your online experience. Learn more
No, thank you accept

Sign in

Don't have an account? Create one

Forgot password?

Select Your Country

Choose your country to see the products for your location

CE

CE-marked products are for In Vitro Diagnostic (IVD) use only in EU (candidate) member states and members of the European Free Trade Association (EFTA), and the UK.

IL

IVD-registered in Israel.